

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

May 27, 2022

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers,
Dalal Street, Mumbai-400001
Script Id: 506365

Subject: Outcome of Board Meeting Held on Friday, May 27, 2022

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. May 27, 2022, have discussed the following matters:


1. Approval of Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2022 along with the Statutory Auditor's Report thereon. The Audit Reports were issued with unmodified opinion of the financial statements.
2. Appointment of M/s. Sarda Soni Associates LLP as an Internal Auditor for the Financial Year 2022-2023.
3. Approval of draft Report of Board of Directors, Management Discussion & Analysis Report along with other supporting documents forming part of Annual Report for the financial year 2021-22.
4. Considered and took on record Secretarial Audit Report issued by M/s Kavita Khatri & Associates, Practicing Company Secretary.

The Meeting commenced at 04.00 p.m. and concluded at 05.15 p.m.

Thanking You.

Yours Faithfully,

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN - 03063364)



Sanjay Rane & Associates

CHARTERED ACCOUNTANTS

C-403, Marathon Next Gen. Innova,
Opp. Peninsula Corporate Park,
Off Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400 013.

Phone : 49198585
Telefax : 49198521
Email : admin@ssrane.net
Website : www.ssraneandco.com

AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To the Board of Directors of CHEMO PHARMA LABORATORIES LIMITED

We have audited the quarterly financial results of Chemo Pharma Laboratories Limited for the quarter ended March 31, 2022 and the year to date results for the period April 1, 2021 to March 31, 2022 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2022 as well as the year to date results for the period from April 1, 2021 to March 31, 2022.

For Sanjay Rane & Associates
Chartered Accountants
Firm Regn. No.: 121089W



CA. Abhijeet Deshmukh
Partner

Membership No. : 129145



Place : Mumbai

Date: 27th May, 2022

UDIN: 22129145AJSBES9983

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2022

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|----------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | | 31st March 2022 | 31st Dec., 2021 | 31st March 2021 | 31st March 2021 | 31st March 2022 |
| | | Audited | Unaudited | Audited | Audited | Audited |
| I | Revenue from Operations | | | - | - | - |
| II | Other Income | 1,288 | 3,613 | 2,574 | 6,680 | 7,889 |
| III | Total Revenue (I + II) | 1,288 | 3,613 | 2,574 | 6,680 | 7,889 |
| IV | Expenses | | | | | |
| | (1) Cost Materials consumed | - | - | - | - | - |
| | (2) Purchase of Stock-in-Trade | - | - | - | - | - |
| | (3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade | - | - | - | - | - |
| | (4) Finance Costs | - | - | - | - | - |
| | (5) Employee Benefits Expenses | 472 | 542 | 367 | 1,262 | 1,731 |
| | (6) Depreciation and Amortisation Expenses | 49 | 50 | 239 | 239 | 189 |
| | (7) Administrative and Other Expenses | 1,340 | 230 | 1,194 | 2,071 | 2,320 |
| | Total Expenses | 1,860 | 822 | 1,800 | 3,572 | 4,240 |
| V | Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV) | (572) | 2,791 | 774 | 3,108 | 3,649 |
| VI | Exceptional Items | - | - | - | - | - |
| VII | Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI) | (572) | 2,791 | 774 | 3,108 | 3,649 |
| VIII | Extra Ordinary Items | - | - | - | - | - |
| IX | Profit/(Loss) before Tax (VII-VIII) | (572) | 2,791 | 774 | 3,108 | 3,649 |
| X | Tax Expenses | | | | | |
| | (1) Current Tax | 631 | - | 503 | 503 | 631 |
| | (2) Tax Adjusted Previous Year | - | - | 104 | 104 | - |
| | (3) Deffered Tax Income | (296) | - | - | - | (296) |
| | (4) MAT Credit Entitlement | (2,285) | - | - | - | (2,285) |
| XI | Profit/(Loss) for the period from continuing operations (IX - X) | 1,378 | 2,791 | 167 | 2,501 | 5,599 |
| XII | Profit/(Loss) from discontinuing operations | - | - | - | - | - |
| XIII | Tax Expenses of discontinuing operations | - | - | - | - | - |
| XIV | Profit/(Loss) from discontinuing operations (after tax) (XII - XIII) | - | - | - | - | - |
| XV | Profit/(Loss) for the period (XI - XIV) | 1,378 | 2,791 | 167 | 2,501 | 5,599 |
| XVI | Other Comprehensive Income | | | | | |
| | A (i) Itmes that will not be reclassified to profit or loss | | | | | |
| | (ii) Income rax relating to items that will not be reclassified to profit or loss | | | | | |
| | B (i) Itmes that will not be reclassified to profit or loss | | | | | |
| | (ii) Income rax relating to items that will not be reclassified to profit or loss | - | - | - | - | - |
| XVII | Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Incoe for the period | 1,378 | 2,791 | 167 | 2,501 | 5,599 |
| XVIII | Earnings per Share : | | | | | |
| | (1) Basic | 0.92 | 1.86 | 0.11 | 1.67 | 3.73 |
| | (2) Diluted | | | | | |

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Standalone Audited Financial Results for the Quarter and Year Ended 31.03.2022 have been reviewed by the Audit Committee in their Meeting held on 27.05.2022 and approved by the Board of Directors of its Meeting held on 27.05.2022. The Audit Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo Pharma Laboratories Limited



Ashok Somani

Ashok Somani
Director

DIN : 03063364

Place : Mumbai

Date : May 27, 2022

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2022 (Rupees in Thousand)

| Sr. No. | PARTICULARS | As at 31.03.2022 Audited | As at 31.03.2021 Audited |
|---------|-----------------------------------------|--------------------------------|--------------------------------|
| 1 | ASSETS | | |
| | (1) Non-Current Assets | | |
| | (a) Property, Plant and Equipement | 391 | 522 |
| | (b) Financial Assets | | |
| | (i) Investments | 29,442 | 407 |
| | (ii) Loans | 21,243 | - |
| | (c) Deffered Tax Assets | 2,581 | - |
| | Total Non-Current Assets | 53,657 | 929 |
| | (2) Current Assets | | |
| | (a) Financial Assets | | |
| | (i) Cash & Cash Equivalents | 6,859 | 21,711 |
| | (ii) Bank Balances other than (i) above | 55,000 | 87,000 |
| | (iii) Other Financial Assets | - | 119 |
| | (b) Current Tax Assets | 1,114 | 773 |
| | Total Current Assets | 62,973 | 1,09,603 |
| | TOTAL ASSETS | 1,16,630 | 1,10,532 |
| 2 | EQUITY AND LIABILITIES | | |
| | (1) Equity | | |
| | (a) Equity Share Capital | 15,000 | 15,000 |
| | (b) Other Equity | 1,00,547 | 94,948 |
| | Total Equity | 1,15,547 | 1,09,948 |
| | (2) Liabilities | | |
| | (1) Current Liabilities | | |
| | (a) Financial Assets | | |
| | (i) Other Financial Liabilities | 52 | 81 |
| | (b) Provisions | 1,031 | 503 |
| | Total Current Liabilities | 1,083 | 584 |
| | TOTAL EQUITY AND LIABILITIES | 1,16,630 | 1,10,532 |

By Order of the Board
For Chemo Pharma Laboratories Limited



Ashok Somani

Ashok Somani
Director

DIN : 03063364

Place : Mumbai

Date : May 27, 2022

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

(Rupees in Thousand)

| PARTICULARS | For the Year Ended March 31, 2022 | For the Year Ended March 31, 2021 |
|---------------------------------------------------------------|-----------------------------------|-----------------------------------|
| A. CASH FLOW FROM OPERATING ACTIVITIES | | |
| Net Profit Before Tax and Extra-ordinary Items | 3,649 | 3,107 |
| Adjustment for : | | |
| Depreciation | 189 | 239 |
| Dividend Income | (1,965) | (4) |
| Interest Income | (4,746) | (5,309) |
| Operating profit before working capital changes | (2,872) | (1,967) |
| Adjustment for | | |
| Increase / (Decrease) in Other Current Liabilities | 498 | (1,368) |
| Decrease / (Increase) in Current Assets | (222) | 128 |
| Purchase of Property, plant and equipment | (59) | (14) |
| Cash Generated From Operations | 217 | (1,254) |
| Taxes Paid | (631) | (863) |
| A. Cash Flow From Operating Activities | (3,286) | (4,083) |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | |
| Dividend Income | 1,965 | 4 |
| Interest Income | 4,746 | 5,309 |
| Purchase / (Sale) of Investment | (29,034) | (170) |
| (Investment) / Proceeds from maturity of fixed deposits (net) | 32,000 | (7,000) |
| Cash Flow From Investing Activities | 9,676 | (1,857) |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | |
| Proceeds from ICD re-paid / (given) | (21,243) | 19,568 |
| Cash Flow From Financing Activities | (21,243) | 19,568 |
| Net Increase/(Decrease) in Cash and Cash Equivalents | (14,852) | 13,627 |
| Opening Balance of Cash and Cash Equivalents | 21,711 | 8,084 |
| Closing Balance of Cash and Cash Equivalents | 6,859 | 21,711 |

For Chemo Pharma Laboratories Limited



Ashok Somani

Ashok Somani
Director

DIN : 03063364

Place: Mumbai

Date: May 27,2022

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2022

(Rupees in Thousand)

| PARTICULARS | STANDALONE | |
|------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| | AUDITED QUARTER ENDED 31.03.2022 | AUDITED YEAR ENDED 31.03.2022 |
| Reconciliation of Profit After Tax as reported earlier: | | |
| Net Profit / (Loss) for the Period (as per AS) | (1,203) | 3,018 |
| Benefit / (Charge): | - | - |
| Impact of Deferred Income (Government Grant) Amortized to Income | - | - |
| Impact of Fair Valuation of Financial Instruments | - | - |
| Impact of Actuarial Gain / Loss Taken OCI | - | - |
| Impact of Adjustment of Deferred Tax Income | 296 | 296 |
| Impact of Adjustment of MAT Credit Entitlement | 2,285 | 2,285 |
| Net Profit / (Loss) for the Period (as per AS) | 1,378 | 5,599 |

For Chemo Pharma Laboratories Limited



Ashok Somani

Ashok Somani
Director
DIN : 03063364

Mumbai, May 27, 2022

CHEMO PHARMA LABORATORIES LIMITED





Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

| | | |
|----|-------------------------------------------------------|--------------------------------------------------------------------------------------|
| 1. | Name of the Company | CHEMO PHARMA LABORATORIES LIMITED |
| 2. | Annual Financial Statements for the year ended | 31 st March, 2022 |
| 3. | Type of Audit observation | Un-Qualified |
| 4. | Frequency of observation | - |
| 5. | To be signed by- | |
| | CEO – Bhavin Sheth |  |
| | CFO – Ashok Somani |  |
| | Auditor of the Company – M/s Sanjay Rane & Associates |  |
| | Audit Committee Chairman – Nandkumar Pareek |  |



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001





• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the Financial Year 2021-2022 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016.

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2021-2022, along with the Audited Financial Results on 27th May, 2022. We hereby confirm that auditors have expressed an unmodified opinion in their Audit Reports on Standalone Financial Statements.

| | | |
|----|-------------------------------------------------------|--------------------------------------------------------------------------------------|
| 1. | Name of the Company | CHEMO PHARMA LABORATORIES LIMITED |
| 2. | Annual Financial Statements for the year ended | 31 st March, 2022 |
| 3. | Type of Audit observation | Un-Qualified |
| 4. | Frequency of observation | - |
| 5. | To be signed by- | |
| | CEO – Bhavin Sheth |  |
| | CFO – Ashok Somani |  |
| | Auditor of the Company – M/s Sanjay Rane & Associates |  |
| | Audit Committee Chairman – Nandkumar Pareek |  |

